jturano7423

MRNA: 9 MONTHS OF STOCK DOWNTREND AND IT IS STILL NOT OVER!

AUG.6-MRNA:NOW $.94 (NO SURPRISE TO ME) I HAVE BEEN THE MOST ACCURATE ON SEEKING ALPHA SINCE SEPTEMBER 2007 ABOUT THIS STOCK WHEN IT WAS CALLED 'NSTK'.
PLENTY OF NEWS ANNOUNCEMENTS, BUT AN AWFUL LONG WAIT TO SEE IF ANY RNAI APPROVED METHODS WILL FINALLLY BE APPROVED. i CALLED FOR NEW LOWS WEEKS AGO, AND EVERY OTHER WEEK IT DOES HIT NEW LOWS. NOW UNDER $1.00 AND MANAGEMENT IS SCRAMBLING FOR A PARTNER TO SURVIVE.

MRNA: 9 MONTHS OF STOCK DOWNTREND AND IT IS STILL NOT OVER!

From $18 dollars to $1.11 and further downtrend is in place.
5 consecutive days of 42,000 to 60,000 shares traded prior to 2 Q earnings report due out by August 4th, 2008. BIG RED FLAG!
direction obvious: $1.00 BID BY AUGUST 21ST., FOLLOWED BY "SEC" ISSUING A 'COMPLIANCE LETTER' THEREAFTER.
JIMMY T.

A Biotech Bloom in July

FANTASTIC ARTICLE! Good job. Of course not all bloomed nicely. There are always some weeds and the SEC should be the ones who pull them out.
Example, 'MRNA'. There has been so much damage to investors to date, that management ought not to be able to continue to pay themselves & exist for another 5,10, or 20 years. A total injustice to all!

General Discussion on NSTK

Friday, July 25th,2008-MRNA-THREE RED FLAGS! CLOSED $1.16 YESTERDAY.
BUT THE THREE RED FLAGS NOW ARE 'NEW RECORD LOW STOCK PRICES RECENTLY,
NEW RECORD LOW EARNINGS REPORTS, AND NOW NEW RECORD LOW ANEMIC SHARE VOLUME.
UNDER 100K THE LAST THREE DAYS, WITH THE LOWEST VOLUME YESTERDAY AT 44,800 SHARES.
EARNINGS REPORT DUE OUT IN 10 DYAS AND IT IS MORE LIKELY THAN NOT THE STOCK PRICE FROM HERE WILL GO DOWN. $1.00 BID BY AUGUST 21 AND SEC COMPLIANCE LETTER TO FOLLOW. THIS IS REALLY A NO BRAINER!

General Discussion on NSTK

MRNA: July 13th-THE CLOCK IS TICKING AND THERE ISN'T MUCH TIME LEFT!
IF YOUR EXPENSES FAR EXCEED YOUR INCOME, HOW MUCH LONGER CAN YOU EXIST?
ASSIDE FROM THE MOST DECIMAL STATISTICS CURRENTLY, THE EARNINGS REPORT THAT IS DUE SOON, THE HUGE DROP IN STOCK PRICE IN THE PAST 12 MONTHS, WAS KMPG, THEIR ACCOUNTANTS, DEAD ON ISSUING A 'GOING CONCERN' LETTER?
BETTER YET, SINCE THE COMPANY SOLD NEW STOCK ISSUANCE TWICE IN 14 MONTHS, DOES THAT MEAN THEY WILL HAVE SUCCESS IN FINDING A PARTNER, IN THE SHAPE THEY ARE IN?
EITHER MANAGEMENT HAS BEEN THE LUCKIEST GROUP OFF PEOPLE ON WALL STREET TO DATE, OR THEIR LUCK MAY RUN OUT! THIS HAS TO MAKE THE BOOK OF GUINNESS RECORDS,
EXISTING FOR 24 YEARS AND ACCOMPLISHING NOTHING BUT INCOME FOR MANAGEMENT.

Jim Cramer's Mad Money Lightning Round Picks, 8/9/07

JULY 11, 2008 FROM JANUARY 2, 2007 UNTIL JULY 11TH, 2008
I HAVE BEEN THE MOST ACCURATE IN FORECASTING, REBUTTING
ARTICLES, RESEARCH FIRMS & THEIR TARGETS, STAR MINE EXPERTS, JIM CRAMER AND HIS TOUTING OF OBESITY WHICH IS OUT THE WINDOW NOW, AND EVERY OTHER FRIEND OR TOUTER OF THE NSTK OR NEW MRNA COMPANY. i HAVE BEEN RATED 5 STAR EXPERT BY PREDICT WALL STREET FOR 12 MONTHS STARIGHT AND HAVE BEEN AN ADVOCATE FOR SHAREHOLDERS WHO HAVE BEEN FLEECED OF THEIR LIFE SAVINGS WHILE MANAGEMENT CONTINUES TO GET PAID AND TO EXIST.

Amylin Has Yet to Crack Tough Diabetes Market

Dear Mr. Saadat,Your precise frank report on diabetes and amln is greatly appreciated. As an investor it is difficult to separate the froth & sometimes hype from research firms to make the proper decisions.
If as you say DIABETES IS A TOUGH MARKET, then how will biotech companies have a chance through RNAI in the next 10 years?
To me this is a gray area yet and may take a decade of testing and approvals. So when certain Biotech companies are solely dependent
on RNAI, promoting RNAI, doesn't the cost factor involved, and the time of potential approvals, far exceed the potential reward when companies are at their earliest stages?
Lastly, why do you think so many investors speculate huge amounts of money in companies that have failed in partnerships, failed in generating income, buy stocks when insiders sell the most stocks in a given year, buy into a stock just because it's down 85% from the year before, and have a blind eye to the research firms who have over touted over shot their target prices for several years in a row?
You and your article are rational in thinking, but others are just compulsive gamblers, and the SEC should post signs like at the Racetracks, that 'GAMBLING IS A DISEASE'.

General Discussion on NSTK

Part 2-Biovest A Risky Bet
David Miller Jun 13, 2008 1:45 pm
Nastech goes RNAi
Nastech, now known as MDRNA (MRNA), is a good example of how tough biotech investing can be. Some smart folks invested in the company, based upon claims by its CEO of a revolutionary drug delivery system that big pharma just couldn’t wait to get its hands on. The claims seemed to be backed up by deeds, in that big pharma did sign deals to investigate the delivery systems.
That approach failed miserably, as the company has essentially abandoned the nasal delivery technology in favor of pursuing an RNA interference strategy. They demoted their CEO, who was the reason I avoided the company, and hired the former CEO of Sirna Therapeutics – which sold itself to Merck (MRK) for a billion dollars a couple of years back.
That brings some instant credibility to the claims MDRNA has legitimate RNAi technology, but critics point to the fact that companies in the RNAi field live and die by patents and MDRNA seems to be a little short in that area. I’m not sure MDRNA needs to have core RNAi patents, however, as they appear to be focusing more on how to deliver RNAi drugs to patients. The issue of delivery is the #1 problem in the RNAi space. If MDRNA has a solution, they could see very significant value growth.
Of course, this is a story we’ve heard already from the company. Encapsulating drugs for easy delivery by nasal spray was the company’s claim to fame – several product failures and two partnership failures ago. I would expect investors to be a little gun-shy this time around, waiting for major investments in MDRNA until the company proves its largely theoretical RNAi delivery system in human trials.
I’ll reiterate my prediction from before – MDRNA’s corporate presentations will be at least as much about the $1B buyout of Sirna and the recent $1B-plus deal RNAi deal between Japan’s Takeda and Alnylam (ALNY) as it will about their own technology. Smart investors will realize there is a big gap between those deals – which involved patent-protected RNAi core technologies – and MDRNA, which is looking only at drug delivery.
When a company blows up investors like Nastech/MDRNA has, it’s always best to make the management team prove they have something in hand instead of investing on the promise they might develop something later.
A NEW CAPTAIN EXCEPT THE SHIP IS FULL OF HOLES!

General Discussion on NSTK

JUNE 15-'MRNA'NEW NAME & NEW SYMBOL FOR NSTK. HEAVYWEIGHT APPOINTED CEO, BUT HE HAS HIS PLATE FULL!
News release within 48 hours of appointment is negative for MRNA
out of the gate! Biovest A Risky Bet
David Miller Jun 13, 2008 1:45 pm


Biotech firm's use of "blinded" curves not a good sign.

Trade free for 30 days + Get $100




Nastech goes RNAi

Nastech, now known as MDRNA (MRNA), is a good example of how tough biotech investing can be. Some smart folks invested in the company, based upon claims by its CEO of a revolutionary drug delivery system that big pharma just couldn’t wait to get its hands on. The claims seemed to be backed up by deeds, in that big pharma did sign deals to investigate the delivery systems.

That approach failed miserably, as the company has essentially abandoned the nasal delivery technology in favor of pursuing an RNA interference strategy. They demoted their CEO, who was the reason I avoided the company, and hired the former CEO of Sirna Therapeutics – which sold itself to Merck (MRK) for a billion dollars a couple of years back.

That brings some instant credibility to the claims MDRNA has legitimate RNAi technology, but critics point to the fact that companies in the RNAi field live and die by patents and MDRNA seems to be a little short in that area. I’m not sure MDRNA needs to have core RNAi patents, however, as they appear to be focusing more on how to deliver RNAi drugs to patients. The issue of delivery is the #1 problem in the RNAi space. If MDRNA has a solution, they could see very significant value growth.

Of course, this is a story we’ve heard already from the company. Encapsulating drugs for easy delivery by nasal spray was the company’s claim to fame – several product failures and two partnership failures ago. I would expect investors to be a little gun-shy this time around, waiting for major investments in MDRNA until the company proves its largely theoretical RNAi delivery system in human trials.

I’ll reiterate my prediction from before – MDRNA’s corporate presentations will be at least as much about the $1B buyout of Sirna and the recent $1B-plus deal RNAi deal between Japan’s Takeda and Alnylam (ALNY) as it will about their own technology. Smart investors will realize there is a big gap between those deals – which involved patent-protected RNAi core technologies – and MDRNA, which is looking only at drug delivery.

When a company blows up investors like Nastech/MDRNA has, it’s always best to make the management team prove they have something in hand instead of investing on the promise they might develop something later.
It goes to show you whether NSTK or MRNA, yes there is a new Jockey(CEO) but it's the same old horse!

General Discussion on NSTK

MRNA
NSTK:
NSTK CHANGES ITS NAME AND NEW SYMBOL IS MRNA.
Welcome j.Michael French
I said for over one year management needs to turn this company around.
This is a positive step for once in altering its course.
As I said also for over one year NSTK needs to change its web site, hopefully that is next!
However the task at hand for the new captain of the ship will not be easy.
Taking over the helm of NSTK/MRNA while it is facing serious business or financial problems, and having posted some of its industry's worst returns on assets, with many failed partnerships, is not like sailing away on a Yacht
on vacation.

However, it is a start, and a long journey that won’t be easy.
Having said that, I will step asside to watch, and observe and give the appropriate chance and evaluate at a later date.

General Discussion on NSTK

TODAY'S NEWS RELEASE INVOLVING 29 PATIENTS WAS GOOD FOR PHASE 2 TRIAL. HOWEVER, LET US FOCUS ON THE MORE IMPORTANT FACTORS. CONTINUANCE LETTER FROM THEIR ACCOUNTANTS, THE FORWARD LOOKING STATEMENT RE:TODAYS NEWS RELEASE HAS MANY IF'S ATTACHED TO IT, WHY DID THEIR CHIEF FINANCIAL OFFICER RESIGN IN JANUARY 2008, WHY DID INSIDERS SELL THE MOST SHARES IN 2007 WHILE RESEARCH FIRMS WERE TOUTING NSTK, AND WHY DID MANAGEMENT GIVES THEMSELVES RAISES AND NEW OPTION BONUSES WHILE TRYING TO RAISE MONEY TO PAY EXPENSES? THIS NEWS RELEASE IS JUST WHAT SHAREHOLDERS NEEDED TO HEAR AFTER THE STOCK HAS BEEN DECIMATED FOR 9 MONTHS STRAIGHT. BUT THE BURN RATE DOESN'T DISAPPEAR AND NOR DOES ITS FAILED PARTNERSHIPS.
THE BIGGER PICTURE REMAINS, THERE HAS BEEN SO MUCH DAMAGE THAT SHAREHOLDERS CAN'T CONTINUE TO HEAR NEWS RELEASES AS THOUGH A MAGICIAN WAS PERFORMING. HEAR & SEE WHAT MANAGEMENT ONLY WANTS YOU TO SEE&HEAR.

RNA Interference Stocks: Invest At Your Own Risk

OH BY THE WAY THE STOCK WENT FROM $18 DOLLARS TO $1.16.
AND THEIR LATEST CONFERENCE CALL WITH THEIR OWN RESEARCH FIRMS THAT FOLLOW NSTK WENT WELL LIKE A PLAY ON BROADWAY!
ON COURSE FOR NEW LOWS, AND $1.00 BID BY AUGUST 21ST.
I STILL WOULD LIKE TO KNOW WHY THEIR CHIEF FINANCIAL OFFICER RESIGNED? SOME RECORD TO DATE & SOME STATISTICS

RNA Interference Stocks: Invest At Your Own Risk

MR.SHULMAN HAS AVOIDED THE QUESTION GOING ON 12 MONTHS SOON. SO I'LL GIVE YOU MY VIEWPOINT THAT HASN'T CHANGED FOR 1 YEAR NOW. THEY TOUT THIS STOCK TO DEATH AND MURPHY'S LAW ALWAYS IS EVER PRESENT. PARTNERSHIPS BREAK UPS ARE COMMON, DILUTION IS CHRONIC, REVENUE IS DOWN, EXPENSES ARE UP, NSTK ACCOUNTS ISSUED A WARNING OF CONTINUANCE LETTER, AND AFTER 24 YEARS THE COMPANY HAS ACCOMPLISHED NOTHING. THE BURN RATE SHOULD BALANCE THEIR RNAI RESEARCH TO A SCREECHING HALT. NOW MR.SCHULMAN YOU CAN START GOING ON YOUR VACATIONS LIKE LAST SUMMER AND ENJOY THE BEACH.

Nastech Pharmaceutical Company Inc. Q1 2008 Earnings Call Transcript

NSTK-JUNE 6, 2008
IT IS FANTASTIC AND UTERLY AMAZING THAT NSTK HAS SO MANY NEWS ANNOUNCEMENTS AND SO MUCH GOOD NEWS FOR 24 STRAIGHT YEARS.
I DON'T SEE HOW AS AN INVESTOR THAT YOU COULDN'T BE HAPPIER.
GREAT MANAGEMENT, GREAT PARTNERSHIPS, GREAT RESULTS, GREAT STATISTICS, AND GREAT REVENUE WITH PLENTY OF NEW ISSUANCE'S OF TOTAL DILUTION OF SHARES.
LETS NOT LEAVE OUT A WONDERFUL STOCK PRICE AS WELL.
BRAVO!

Nastech Pharmaceutical Company Inc. Q1 2008 Earnings Call Transcript

THIS ARE THE OLD CHUMS OF NSTK
Analysts
Alex Quint - Quint Miller & Company
Bert Hazlett - BMO Capital Markets
Yale Jen - Maxim Group
Andrew Riley - Ponfit Partners
Eli Hollander - Private Investor

OUTPERFORMS-HIGH TARGET PRICES AND BURNED SHAREHOLDERS TO DATE. NOW THEY WANT TO START A NEW PROJECT FOR THE NEXT 25 YEARS AND GET NEW SHAREHOLDERS ONCE AGAIN.
I DON'T THINK SO.
P.S. GIVE MY REGARDS TO THE SEC!